ClinicalTrials.govpublic full text
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
epithelial ovarian cancer, primary peritoneal, fallopian tube cancer, newly diagnosed, figo stage iii-iv, partial response, complete response, parp inhibitor, parpi, hrd, athena, homologous recombination
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 881753
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.